RTT News - Product Sales Up - Quick Facts [OSIR] 11/12/2007 6:12:49 AM Osiris Therapeutics, Inc. (OSIR) reported a third quarter net loss of $10.4 million or $0.36 per share, compared to a loss of $15.6 million or $0.75 per share in the last year quarter. Product
Source: www.rttnews.com
Patni Computer Reveals Multi-year, US$200 Mln Deal With Carphone
RTT News - Osiris Therapeutics Gets FDA Clearance To Begin Phase III Trial For Prochymal [OSIR] 10/17/2007 8:50:02 AM Osiris Therapeutics, Inc. (OSIR) on Wednesday revealed the commencement of Phase III pivotal trial evaluating Prochymal as a first line agent in
Source: www.rttnews.com
Evaluating An Immunomodulatory Cell Therapy Product For Type 1
Medical News Today - The Juvenile Diabetes Research Foundation has announced a partnership with Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support a Phase II clinical trial using Prochymal, an immunomodulatory cell therapy product, to preserve and regenerate insulin
Source: www.medicalnewstoday.com
Tuesday’s Health Winners & Losers
Street.Com - Osiris Therapeutics ( OSIR - Cramer’s Take - Stockpickr ) gave positive interim, one-year results of a 55-patient, phase I/II trial evaluating Chondrogen, a preparation of adult stem cells formulated to be injected into the knee. The company said the one
Source: www.thestreet.com
Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating
Forbes - Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced the initiation of a Phase II clinical trial evaluating Prochymal, a stem cell therapy, as a treatment for type 1 diabetes. Through a partnership with the Juvenile Diabetes Research Foundation
Source: www.forbes.com